Đang chuẩn bị liên kết để tải về tài liệu:
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

KRAS mutations occur frequently in advanced non-small cell lung cancer (aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11 or KEAP1 commonly co-occur with KRAS mutations in aNSCLC. |

TÀI LIỆU LIÊN QUAN

CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy

The effects of physical activity on overall survival among advanced cancer patients: A systematic review and meta-analysis

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial

Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: A multicenter retrospective study

Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving frst-line immunotherapy: A multicenter retrospective study

Real-world treatment and survival of patients with advanced non-small cell lung Cancer: A German retrospective data analysis

The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/ chemoradiotherapy: A meta-analysis

DocOx (AIO-PK0106): A phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemoradiotherapy